Abstract 449: Discovery of novel MTA-cooperative PRMT5 inhibitors as targeted therapeutics for MTAP-deleted cancers
Authors: Bartosik Anna , Radzimierski Adam , Bobowska Aneta , Levenets Oleksandr , Stachowicz Agata , Kuś Kamil , Michalik Kinga , Banaszak Katarzyna , Madej Monika , Skoda Marta , Kozłowska-Tomczyk Kamila , Tomczyk Igor , Pyziak Karolina , Krzemień Dobrosława , Gładysz Mirosława , Podkalicka Paulina , Gołas Aniela , Gluza Karolina , Satała Grzegorz , Gondela Andrzej , Sowińska Marta , Boutard Nicolas , Chłopek Agata , Więckowska Aleksandra , Szukiel Daria , Ćwiertnia Grzegorz , Levenets Iana , Zuchowicz Karol , Korta-Piątek Klara , Nowogródzki Marcin , Wronowski Marek , Girardi Marianna , Świrski Mateusz , Popika Oleksandr , Niedziejko-Ćwiertnia Paulina , Cordone Pierpaolo , Wyrębek Przemysław , Vũ Quỳnh , Sasmal Sujit , Sukhomlinova Svitlana , Miodek Magdalena , Faber Jacek , Kowal-Chwast Anna , Starczak Róża , Ratajczak Sanja Novak , Świrska Agnieszka , Gogola Dawid , Guzik Paweł , Swarbrick Martin , Nowak Mateusz 
Published: April 2023

Homozygous deletions of p16/CDKN2a (cyclin dependent kinase inhibitor 2A) locus are prevalent in cancer and often involve co-deletion of adjacent genes. Metabolic gene MTAP (methylthioadenosine phosphorylase) is localized at the 9p21 chromosome in the close proximity to p16/CDKN2A tumor-suppressor locus. Co-deletion of MTAP may be observed in 80-90% of all tumors harboring homozygous deletion of CDKN2A, which represents 10 - 15% of all human tumors. Many of these tumor types, such as non-small cell lung cancer, pancreatic adenocarcinoma, glioblastoma or mesothelioma are associated with poor prognosis, representing a significant unmet medical need. MTAP deletion results in a massive accumulation of methylthioadenosine (MTA) in cells. MTA in high concentrations is a very selective inhibitor of PRMT5 methyltransferase, competitive for the substrate: S-adenosylmethionine (SAM). Accumulation of MTA in cells with MTAP deletion causes partial inhibition of the methylation activity of PRMT5, which in turn reduces the level of symmetric arginine dimethylation of the whole proteome, and thus an increased sensitivity of cells to modulation of methylosome activity. Therapeutic targeting of PRMT5 in homozygous MTAP-deleted cancers constitute a promising strategy of selective killing of genetically defined cancer cells. Ryvu has identified a series of MTA-cooperative PRMT5 inhibitors which have good drug-like physicochemical properties and block methyltransferase activity with nanomolar IC50 values. Structurally enabled hit generation and optimization allowed quick expansion and delivery of several generations of compounds with novel IP, high target engagement in cells and selective potency in MTAP-deleted cell lines. Ryvu compounds selectively inhibit growth of MTAP-deleted cancer cells in prolonged 3D culture, which strongly correlates with inhibition of PRMT5-dependent protein symmetric dimethylation (SDMA) in those cells. Selectivity between effects observed in MTAP-deleted and WT cells exceeds 100-fold both for SDMA and growth inhibition. The DMPK profile of these compounds allows for oral administration, which enables testing antitumor activity in MTAP null tumor xenograft-bearing mice. Efficacy studies with our lead compound resulted in demonstration of tumor growth inhibition in MTAP -/- model, accompanied by significant inhibition of target proximal PD biomarker.  Overall, these studies provide a rationale for further optimization of our chemical series of MTA-cooperative PRMT5 inhibitors towards a clinical candidate. 

Citation Format: Anna Bartosik, Adam Radzimierski, Aneta Bobowska, Oleksandr Levenets, Agata Stachowicz, Kamil Kuś, Kinga Michalik, Katarzyna Banaszak, Monika Madej, Marta Skoda, Kamila Kozłowska-Tomczyk, Igor Tomczyk, Karolina Pyziak, Dobrosława Krzemień, Mirosława Gładysz, Paulina Podkalicka, Aniela Gołas, Karolina Gluza, Grzegorz Satała, Andrzej Gondela, Marta Sowińska, Nicolas Boutard, Agata Chłopek, Aleksandra Więckowska, Daria Szukiel, Grzegorz Ćwiertnia, Iana Levenets, Karol Zuchowicz, Klara Korta-Piątek, Marcin Nowogródzki, Marek Wronowski, Marianna Girardi, Mateusz Świrski, Oleksandr Popika, Paulina Niedziejko-Ćwiertnia, Pierpaolo Cordone, Przemysław Wyrębek, Quỳnh Vũ, Sujit Sasmal, Svitlana Sukhomlinova, Magdalena Miodek, Jacek Faber, Anna Kowal-Chwast, Róża Starczak, Sanja Novak Ratajczak, Agnieszka Świrska, Dawid Gogola, Paweł Guzik, Martin Swarbrick, Mateusz Nowak. Discovery of novel MTA-cooperative PRMT5 inhibitors as targeted therapeutics for MTAP-deleted cancers  [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 449.